Patents by Inventor William Paul Esler

William Paul Esler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR
    Publication number: 20230405002
    Abstract: Described herein are pharmaceutical compositions comprising 2-{5-[(3-ethoxypyridin-2-yl)oxy]pyridin-3-yl}-N-[(3S,5S)-5-fluoropiperidin-3-yl]pyrimidine-5-carboxamide, or pharmaceutically acceptable salt thereof, for treatment of liver disease and diseases related thereto. Also described are compositions comprising 2-{5-[(3-ethoxypyridin-2-yl)oxy]pyridin-3-yl}-N-[(3S,5S)-5-fluoropiperidin-3-yl]pyrimidine-5-carboxamide, or pharmaceutically acceptable salt thereof and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypyridin-2-yl)benzoic acid, or pharmaceutically acceptable salt thereof, for treatment of liver disease and diseases related thereto.
    Type: Application
    Filed: February 22, 2021
    Publication date: December 21, 2023
    Applicant: Pfizer Inc.
    Inventors: Neeta Balkrishan Amin, Arthur James Bergman, Roberto Arnaldo Calle, Robert Gregory Dullea, David James Edmonds, William Paul Esler, Kevin James Filipski, James Richard Gosset, Albert Myung Kim, Jeffrey Allen Pfefferkorn, Patrick Robert Verhoest
  • Combinations for Treatment of NAFLD/NASH and Related Diseases
    Publication number: 20230218616
    Abstract: A method for treating fatty liver disease and related diseases or disorders with a therapeutically effective amount of a composition comprising from about 25 mg to about 1200 mg of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof, and from about 5 mg to about 40 mg of 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 22, 2021
    Publication date: July 13, 2023
    Applicant: Pfizer Inc.
    Inventors: Neeta Balkrishan Amin, Arthur James Bergman, Roberto Arnaldo Calle, William Paul Esler, Albert Myung Kim, Jeffrey Allen Pfefferkorn, Patrick Robert Verhoest
  • Combinations for treatment of NASH/NAFLD and related diseases
    Patent number: 11254660
    Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: February 22, 2022
    Assignee: Pfizer Inc.
    Inventors: William Paul Esler, Trenton Thomas Ross
  • Combinations For Treatment Of NASH/NAFLD And Related Diseases
    Publication number: 20220023299
    Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
    Type: Application
    Filed: October 11, 2021
    Publication date: January 27, 2022
    Applicant: Pfizer Inc.
    Inventors: William Paul Esler, Trenton Thomas Ross
  • Combinations For Treatment Of NASH/NAFLD And Related Diseases
    Publication number: 20200071306
    Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
    Type: Application
    Filed: August 28, 2019
    Publication date: March 5, 2020
    Applicant: Pfizer Inc.
    Inventors: William Paul Esler, Trenton Thomas Ross
  • USE OF ACETYL-COA CARBOXYLASE INHIBITORS FOR TREATING ACNE VULGARIS
    Publication number: 20160220557
    Abstract: The present invention relates to methods of treating and/or preventing acne in patients comprising the step of administering to patients in need of such treatment a therapeutically effective amount of an ACC inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 29, 2014
    Publication date: August 4, 2016
    Applicant: Pfizer Inc.
    Inventors: William Paul Esler, Gabriele Elisabeth Sonnenberg